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Abstract 
Background: Streptomyces albus J1074 produces glycosylated antibiotics paulomycin A, B and E that derive from 
chorismate and contain an isothiocyanate residue in form of paulic acid. Paulomycins biosynthesis pathway involves 
two glycosyltransferases, three acyltransferases, enzymes required for paulic acid biosynthesis (in particular an ami-
notransferase and a sulfotransferase), and enzymes involved in the biosynthesis of two deoxysugar moieties: D-allose 
and L-paulomycose.
Results: Inactivation of genes encoding enzymes involved in deoxysugar biosynthesis, paulic acid biosynthesis, 
deoxysugar transfer, and acyl moieties transfer has allowed the identification of several biosynthetic intermediates 
and shunt products, derived from paulomycin intermediates, and to propose a refined version of the paulomycin 
biosynthesis pathway. Furthermore, several novel bioactive derivatives of paulomycins carrying modifications in the 
L-paulomycose moiety have been generated by combinatorial biosynthesis using different plasmids that direct the 
biosynthesis of alternative deoxyhexoses.
Conclusions: The paulomycins biosynthesis pathway has been defined by inactivation of genes encoding gly-
cosyltransferases, acyltransferases and enzymes involved in paulic acid and L-paulomycose biosynthesis. These 
experiments have allowed the assignment of each of these genes to specific paulomycin biosynthesis steps based 
on characterization of products accumulated by the corresponding mutant strains. In addition, novel derivatives of 
paulomycin A and B containing L-paulomycose modified moieties were generated by combinatorial biosynthesis. 
The production of such derivatives shows that L-paulomycosyl glycosyltransferase Plm12 possesses a certain degree 
of flexibility for the transfer of different deoxysugars. In addition, the pyruvate dehydrogenase system form by Plm8 
and Plm9 is also flexible to catalyze the attachment of a two-carbon side chain, derived from pyruvate, into both 
2,6-dideoxyhexoses and 2,3,6-trideoxyhexoses. The activity of the novel paulomycin derivatives carrying modifications 
in the L-paulomycose moiety is lower than the original compounds pointing to some interesting structure–activity 
relationships.
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Background
Bacterial genomes sequencing and mining has become 
a powerful tool to identify biosynthesis gene clusters 
leading to produce novel secondary metabolites [1–3] 
and to study the biosynthesis pathway of known com-
pounds [4–6]. Actinomycetes, in particular genus Strep-
tomyces, are now one of the most highly sequenced 
microorganisms because of their industrial and pharma-
ceutical relevance as producers of enzymes and bioactive 
compounds [7]. The growing availability of actinomycete 
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genome sequences has allowed intra- and inter-species 
comparison of genomes and secondary metabolite bio-
synthesis gene clusters leading to identify novel path-
ways and to gather increasing insights about evolution 
of genomes and secondary metabolism [8–11]. Intensive 
genome mining studies has been applied to Streptomyces 
albus strains isolated from diverse environmental niches 
resulting in the identification of a total of 48 unique bio-
synthetic gene clusters harbored by seven strains [12]. In 
particular, S. albus J1074 is the one drawing more atten-
tion since it is widely use as host for heterologous pro-
duction of bioactive natural products [13, 14]. S. albus 
J1074, derivative of S. albus G defective in both restric-
tion and modification enzymes of the SalI system [15], 
has been shown to produce, under different conditions 
and manipulation techniques, several carotenoids [16], 
hybrid polyketide-non-ribosomal peptides antimycins 
and 6-epi-alteramides, type I polyketides candicidins and 
non-ribosomal peptide indigoidine [14]. In addition, S. 
albus J1074 produces glycosylated compounds paulomy-
cin A, B and E, and their derivatives paulomenol A and 
B (Fig. 1) [14], generated by the spontaneous loss of the 
paulic acid moiety.
Paulomycins A and B antibiotics containing an iso-
thiocyanate group (paulic acid) and mainly active 
against Gram-positive bacteria, were initially isolated 
from Streptomyces paulus strain 273 [17, 18]. Later 
on, the absolute stereochemistry of these compounds 
was reported [19, 20] and they were found to be closely 
related to antibacterial compounds senfolomycins A and 
B, only differing in the stereochemistry of methoxy group 
present in their respective deoxysugar moieties [21]. 
Streptomyces paulus produces paulomycins as a family 
of compounds that include paulomycin A, A2, B, C, D, E 
and F [22], O-demethylpaulomycins A and B, paulomenol 
A and B, hydrogen sulfide adducts of paulomycin A and B 
[23], paldimycin A and B, and 273a2α and 273a2β, deriva-
tives of paulomycin A and paulomycin B containing one 
or two N-acetyl-l-cysteine groups, respectively [24, 25]. 
Antibiotic activity of paldimycins was assessed in  vitro 
against 215 Gram-positive bacteria and found compara-
ble to that of vancomycin [26]. In addition, paulomycins 
and paldimycins were found to be able of killing Staphy-
lococcus aureus intracellular cells surviving into poly-
morphonuclear leukocytes [27, 28]. On the other hand, 
paulomenol A and B lack antibacterial activity pointing 
to paulic acid as determinant of the antibiotic proper-
ties of paulomycins and paldimycins [23]. Paulomycin A 
and B were also found to be produced by S. albus G [29]. 
Regarding the biosynthetic origin of paulomycins, addi-
tion of some precursors was found to increase produc-
tion yields and they included valine, isoleucine, isobutyric 
acid, 2-methylburytic acid [30], l-methionine, l-thre-
onine and α-ketoburyric acid [31, 32]. The gene cluster 
involved in paulomycins biosynthesis has been recently 
reported in S. albus J1074 [14], S. paulus NRRL8115 and 
Streptomyces sp. YN86 [33] sharing between them an 
overall identity of 99 %. A pathway for paulomycin bio-
synthesis in S. paulus NRRL8115, based on in silico gene 
analysis, has been recently proposed [33].
In this work, we characterize several steps of pau-
lomycins biosynthesis in S. albus J1074 including the 
Fig. 1 Chemical structures of paulomycins and paulomenols
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glycosylation and acylation steps and the biosynthesis of 
the paulic acid moiety. Inactivation experiments allowed 
to determine genes (and enzymes) involved in these 
steps and to identify several biosynthetic intermediates 
and some products accumulated by the correspond-
ing mutants which provided insights on the biosynthe-
sis pathway. One of the genes studied in this work, and 
shown to be involved in paulomycin biosynthesis, has 
not been previously annotated at S. paulus NRRL8115 
and Streptomyces sp. YN86 paulomycin biosynthesis gene 
clusters. We propose a refined version of the paulomycin 
biosynthesis pathway based on experimental evidence. 
In addition, we have generated by combinatorial biosyn-
thesis several novel bioactive derivatives of paulomycin A 
and B carrying modifications in the L-paulomycose moi-
ety using different plasmids that direct the biosynthesis 
of different deoxyhexoses.
Results
Delimiting the boundaries of paulomycin biosynthesis 
cluster
Paulomycin biosynthesis gene cluster (Fig.  2a, Table  1) 
was initially delimited by sshg_05313 and sshg_05354 
using an in silico analysis [14]. Boundaries of the cluster 
have now been further defined by RT-PCR gene expres-
sion analysis using S. albus J1074 total RNA as a template, 
isolated at 48  h from cultures grown in R5A that were 
producing paulomycins and paulomenols. Under condi-
tions of paulomycin production, in the upstream region 
only sshg_05314 and sshg_05315 were transcribed, 
while in the downstream region were sshg_05354 and 
sshg_05355 (Fig. 2b). These results pointed to sshg_05314 
and sshg_05355 as gene cluster boundaries. These results 
were verified by inactivation of several genes. Inactivation 
of sshg_05314, encoding a LuxR-family transcriptional 
regulator, led to SAM5314 mutant strain, which was 
still able to produce paulomycin A (1), B (2), E (3), pau-
lomenol A (4) and B (5) but at considerably lower yield 
(20  %) than S. albus J1074 (Fig.  2c). This result points 
to sshg_05314 as involved in regulation of paulomy-
cin biosynthesis. Complementation of SAM5314 using 
pEM4HT5314 restored paulomycin production to wild 
type strain levels (Additional file  1: Figure S5). On the 
contrary, inactivation of sshg_05312, SAM5312 mutant 
strain, had no effect on paulomycin production (Fig. 2c). 
Otherwise, inactivation of sshg_05313 encoding a TetR-
family transcriptional regulator, led to SAM5313 mutant 
strain, which accumulates more paulomycin B (2) and 
paulomenol B (5), 2- and 1.5-fold respectively, than the 
wild type strain (Fig. 2c). This result points to sshg_05313 
as involved in regulation of paulomycin biosynthe-
sis as a repressor. Considering that under conditions of 
Fig. 2 Paulomycin biosynthesis gene cluster. a S. albus J1074 genome region containing the paulomycin biosynthesis gene cluster. Bars rep-
resent genes at cluster boundaries analyzed by RT-PCR. b RT-PCR gene expression analysis of genes delimiting paulomycin biosynthesis gene 
cluster boundaries: sshg_05312, sshg_05313 (plm1), sshg_05314 (plm2), sshg_05315 (plm3), sshg_05353 (plm41), sshg_05354 (plm42) sshg_05355 
and sshg_05356. c UPLC chromatograms, monitored at 244 nm, of S. albus J1074 and SAM5314, SAM5312, SAM5313 and SAM5355 mutant strains. 
Labeled peaks correspond to paulomycins A (1), B (2) and E (3), and paulomenols A (4) and B (5)
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Table 1 Proposed functions of paulomycin biosynthesis cluster deduced proteins from S. albus J1074
S. albus J1074a Cluster proteins Proposed function S. paulus NRRL8115b Streptomyces sp. YN86c
SSHG_05310 RNA polymerase sigma factor Pau1 (98/98) PauY1 (98/99)
SSHG_05311 M23 family peptidase Pau2 (99/100) PauY2 (99/100)
SSHG_05312 Putative aminotransferase Pau3 (100/100) PauY3 (99/99)
SSHG_05313 Plm1 TetR-family transcriptional regulator Pau4 (99/100) PauY4 (100/100)
SSHG_05314 Plm2 LuxR-family transcriptional regulator Pau5 (94/94) PauY5 (96/96)
SSHG_05315 Plm3 Isovaleryltransferase Pau6 (100/100) PauY6 (99/99)
SSHG_05316 Plm4 Oxidoreductase Pau7 (100/100) PauY7 (98/99)
SSHG_05317 Plm5 Conserved hypothetical protein Pau8 (100/100) PauY8 (100/100)
SSHG_05318 Plm6 EmrB/QacA subfamily transporter Pau9 (100/100) PauY9 (99/99)
SSHG_05319 Plm7 Elongation factor G 1 Pau10 (99/99) PauY10 (99/99)
SSHG_05320 Plm8 Dehydrogenase E1 alpha subunit Pau11 (100/100) PauY11 (99/99)
SSHG_05321 Plm9 Dehydrogenase E1 beta subunit Pau12 (99/99) PauY12 (99/99)
SSHG_05322 Plm10 SARP-family transcriptional regulator Pau13 (99/100) PauY13 (100/100)
SSHG_05323 Plm11 Cytochrome P450-like Pau14 (99/99) PauY14 (98/99)
SSHG_05324 Plm12 Glycosyltransferase Pau15 (99/99) PauY15 (99/99)
SSHG_05325 Plm13 NDP-hexose 2,3-dehydratase Pau16 (99/99) PauY16 (99/99)
SSHG_05326 Plm14 3-hydroxybenzoate 6-hydroxylase Pau17 (99/100) PauY17 (99/99)
SSHG_05327 Plm15 Anthranilate synthase Pau18 (99/99) PauY18 (99/99)
SSHG_05328 Plm16 Isochorismatase Pau19 (99/99) PauY19 (99/99)
SSHG_05329 Plm17 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase Pau20 (99/99) PauY20 (99/99)
SSHG_05330 Plm18 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase Pau21 (99/99) PauY21 (99/99)
SSHG_05331 Plm19 Predicted GCN5-related N-acetyltransferase – –
SSHG_05332 Plm20 dTDP-glucose 4,6-dehydratase Pau22 (99/99) PauY22 (99/99)
SSHG_05333 Plm21 D-glucose-1-phosphate synthase Pau23 (99/99) PauY23 (99/99)
SSHG_05334 Plm22 Isovaleryltransferase Pau24 (99/99) PauY24 (99/99)
SSHG_05335 Plm23 C-glycosyltransferase Pau25 (100/100) PauY25 (99/99)
SSHG_05336 Plm24 Glyoxalase Pau26 (99/100) PauY26 (99/100)
SSHG_05337 Plm25 FAD-binding monooxygenase Pau27 (99/100) PauY27 (99/99)
SSHG_05338 Plm26 Hypothetical protein, Reductase Pau28 (99/99) PauY28 (99/99)
SSHG_05339 Plm27 3-oxoacyl-ACP synthase III Pau29 (99/99) PauY29 (100/100)
SSHG_05340 Plm28 Putative sulfotransferase Pau30 (100/100) PauY30 (99/98)
SSHG_05341 Plm29 Aminotransferase Pau31 (99/100) PauY31 (98/98)
SSHG_05342 Plm30 LuxR-family transcriptional regulator Pau32 (100/100) PauY32 (100/100)
SSHG_05343 Plm31 Oxidoreductase Pau33 (99/99) PauY33 (98/98)
SSHG_05344 Plm32 Acyl-CoA synthase Pau34 (99/99) PauY34 (100/100)
SSHG_05345 Plm33 Acyl-carrier protein Pau35 (100/100) PauY35 (100/100)
SSHG_05346 Plm34 Dihydrodipicolinate reductase Pau36 (100/100) PauY36 (100/100)
SSHG_05347 Plm35 Ribulose-5-phosphate 4-epimerase Pau37 (99/99) PauY37 (100/100)
SSHG_05348 Plm36 4′-phosphopantetheinyl transferase Pau38 (99/99) PauY38 (100/100)
SSHG_05349 Plm37 Acyl-CoA dehydrogenase Pau39 (99/100) PauY39 (99/99)
SSHG_05350 Plm38 Hypothetical protein Pau40 (98/100) PauY40 (97/99)
SSHG_05351 Plm39 Pyranose oxidase Pau41 (100/100) PauY41 (100/100)
SSHG_05352 Plm40 dTDP-4-keto-6-deoxy-L-hexose 2,3-reductase Pau42 (99/99) PauY42 (99/99)
SSHG_05353 Plm41 dTDP-6-deoxy-L-hexose 3-O- methyltransferase Pau43 (100/100) PauY43 (100/100)
SSHG_05354 Plm42 dTDP-4-keto-6-deoxyhexose 3,5-epimerase Pau44 (100/100) PauY44 (100/100)
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paulomycin production sshg_05313 is not transcribed 
it might be acting as a repressor of the pathway at early 
stages of S. albus growth when paulomycins are not pro-
duced. These results led to establish the left-hand limit 
of the cluster at sshg_05313 (Fig.  2a). Inactivation of 
sshg_05355 led to SAM5355 mutant strain that produced 
paulomycins and paulomenols at the same level than S. 
albus J1074 wild type strain (Fig.  2c). Since sshg_05354 
encodes a dTDP-4-keto-6-deoxyhexose 3,5-epimerase, 
which has been proposed to be involved in 2,6-deox-
ysugar paulomycose biosynthesis [14] and is expressed 
during paulomycins biosynthesis (Fig.  2b), it should be 
the left-hand limit of this cluster (Fig. 2a). According to 
these results, from here on out, we will designate the 
paulomycin biosynthesis genes as plm1 (corresponding 
to sshg_05313) to plm42 (corresponding to sshg_05354) 
(Fig. 2a, Table 1). The boundaries of the paulomycin clus-
ter at S. paulus NRRL8115 have been previously delim-
ited to pau4 and pau44 [33], genes that correspond to S. 
albus orthologues plm1 and plm42 (Table 1).
Regulation of paulomycin biosynthesis gene cluster
In addition to plm1 and plm2, two more genes, plm10 and 
plm30, might be involved in regulation of paulomycin bio-
synthesis. Plm10 shows similarity to transcriptional regu-
lators of SARP-family and Plm30 might correspond to the 
LuxR-family of transcriptional regulators. In both cases, 
these putative regulatory proteins present orthologues 
(Pau13/PauY13 and Pau32/PauY32, respectively) into pau-
lomycin biosynthesis clusters in S. paulus (KJ721164.1) 
and Streptomyces sp.YN86 (KJ721165.1). Independent 
inactivation of plm10 and plm30 led to SAM5322 and 
SAM5342 mutant strains, respectively. Both mutants 
were unable to produce paulomycins A and B or their 
derivatives paulomenols A and B (Fig. 3), confirming the 
role of plm10 and plm30 as positive regulators in paulo-
mycin biosynthesis. Both mutant strains were growing 
at the same rate as the wild type strains measured by dry 
weight. Complementation of SAM5322 and SAM5342 
using pEM4HTSARP and pEM4HTLuxR, respectively, 
partially restored (20  % in each case) paulomycins and 
paulomenols production (Additional file 1: Figure S5).
Glycosyltransferases involved in paulomycin biosynthesis
Two glycosyltransferases must be involved in the 
incorporation of D-allose and L-paulomycose during 
paulomycin biosynthesis. Plm12 and Plm23 show simi-
larities to O- and C-glycosyltransferases from different 
streptomycetes including Pau15/PauY15 and Pau25/
PauY25, respectively, of paulomycin biosynthesis clus-
ters in S. paulus (KJ721164.1) and Streptomyces sp.YN86 
(KJ721165.1). In addition, Plm11 shows similarity to 
cytochrome P450-like enzymes that lack the conserved 
Cys necessary to bind heme prosthetic group. These 
enzymes have been shown to participate in glycosylation 
by activating their counterpart glycosyltransferase [34].
Inactivation of plm12 led to SAM5324 mutant strain 
(Fig. 4), unable to produce paulomycins A or B but pro-
ducing instead a compound (6) with UPLC retention 
time of 3.17  min, showing the characteristic paulomy-
cin absorption spectrum with maxima at 236, 275 and 
323 nm, and a mass of m/z 473 [M + H]+. The similar-
ity of compound 6 and paulomycins absorption spec-
tra pointed to the presence of paulic acid in 6 structure. 
Furthermore, compound 6 mass is in concordance with 
paulomycin intermediate 6-hydroxyl-paulinone (Fig.  5). 
The correlation of S. albus J1074 proteins with orthologues from S. paulus NRRL8115 and Streptomyces sp. YN86 paulomycin biosynthesis gene clusters is shown
a  Proteins corresponding to nucleotide accession number NZ_DS999645.1
b  Proteins corresponding to nucleotide accession number KJ721164.1. % identity/similarity (in parenthesis)
c  Proteins corresponding to nucleotide accession number KJ721165.1. % identity/similarity (in parenthesis)
Fig. 3 Characterization of regulatory genes. UPLC chromatograms, 
monitored at 244 nm, of S. albus J1074 and SAM5322 and SAM5342 
mutant strains. All extracts were generated by culturing mutant 
strains in R5A liquid medium during 96 h. Labeled peaks correspond 
to paulomycin A (1), paulomycin B (2), paulomenol A (4) and pau-
lomenol B (5)
S. albus J1074a Cluster proteins Proposed function S. paulus NRRL8115b Streptomyces sp. YN86c
SSHG_05355 Malate synthase Pau45 (99/100) PauY45 (99/100)
SSHG_05356 Oxidoreductase Pau46 (97/98) PauY46 (98/98)
SSHG_05357 Oxidoreductase Pau47 (100/100) PauY47 (99/99)
Table 1 contiuned
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In consonance with this, compound 6 was converted 
into paulomycin A (1) and B (2) by co-culturing S. albus 
B29 strain, a mutant altered at early steps in paulomy-
cin biosynthesis [14], and SAM5324. The same result 
was obtained by co-culturing SAM5335 (see below) and 
SAM5324 mutant strains (Additional file  2: Figure S6). 
6-hydroxyl-paulinone (6) suffers, during its purification 
and analysis, an acyl migration of the paulic acid moiety. 
Thus, characterization of this compound by NMR (Addi-
tional file  3: Figures S8–S14, Table S2) identified it as 
6-hydroxyl-13-O-paulyl-paulinone (6′) (Fig. 5), which in 
fact contains a paulic acid moiety that has migrated from 
its normal position at C11 hydroxyl group (D-allose C4) 
to C13 hydroxyl moiety (D-allose C6). 6-hydroxyl-13-O-
paulyl-paulinone (6′) is not a real paulomycin biosyn-
thetic intermediate since no conversion to paulomycin A 
and B was observed by feeding 6′ to S. albus B29 mutant 
strain. SAM5324 produced, in addition, a second com-
pound (7) with UPLC retention time of 4.07 min, absorp-
tion spectrum with maxima at 269 and 316  nm, and a 
mass of m/z 460 [M + H]+. This compound was charac-
terized by NMR (Additional file 3: Figures S15–S19, Table 
S3) as (2E)-17-(4′-aminophenyl)-3,11,15-trihydroxy-
10,12,14-trimethyl-17-oxo-heptadeca-4,6,8-trienoic 
acid (Fig.  5), showing no structural relationship with 
paulomycins and corresponding to an incomplete inter-
mediate of candicidin. This compound might result from 
the accumulation of chorismate and its conversion into 
p-aminobenzoic acid (PABA), direct precursor of candi-
cidins (Fig. 5).
SAM5335 mutant strain, which was generated by dele-
tion of plm23, produces four compounds (Fig.  4) with 
UPLC retention times of 2.0, 2.7, 2.9 and 3.0 min, respec-
tively. Compound 8 with UPLC retention time of 2.0 min, 
showed maxima of absorbance at 223 and 329 nm, and a 
mass of m/z 138 [M + H]+. It was identified as 2-amin-
obenzoic acid (anthranilic acid) (Fig. 5) by NMR (Addi-
tional file  3: Figures S20–S23, Table S4). Compounds 9 
and 10 with UPLC retention times of 2.7 and 2.9  min, 
respectively, shared a similar absorption spectrum with 
maxima at 223, 251 and 302 nm. Compound 10, revealed 
by mass analysis an ion of m/z 180 [M + H]+, and was 
identified by NMR (Additional file  3: Figures S24–S26) 
as N-acetyl-orto-benzoic acid (Fig.  5). Compound 11 
with UPLC retention times of 3.0 min, a mass of m/z 209 
[M + H]+ and maxima of absorption at 207 and 288 nm, 
was characterized by NMR (Additional file  3: Figures 
S27–S29) as deoxydehydrochorismic acid (Fig. 5). These 
compounds, 2-aminobenzoic acid (8), N-acetyl-orto-ben-
zoic acid (10) and deoxydehydrochorismic acid (11), are 
not paulomycin intermediates since they failed restoring 
paulomycins biosynthesis in bioconversion experiments 
using S. albus B29 mutant strain. Complementation 
of SAM5324 and SAM5335 using pEM4HT5324 and 
pEM4HT5335 respectively, partially restored (20  % and 
10  %, respectively) paulomycins and paulomenols pro-
duction (Additional file 1: Figure S5).
Acyltransferases involved in paulomycin biosynthesis
Three acyltransferases might be involved in the incor-
poration of paulyl-CoA, acyl-CoA and 2-methylbutyryl-
CoA or isobutyryl-CoA during paulomycin A and B 
biosynthesis, respectively. Plm3 and Plm22 show similar-
ity to O-acyltransferases MegY (AAG13909.1) and TcaM 
(ACB37733.1) involved in megalomicin and tetrocar-
cin A biosynthesis, respectively. In addition, they show 
similarity to isovaleryltransferases from different origins 
including Pau6/PauY6 and Pau24/PauY24, respectively, 
in S. paulus (KJ721164.1) and Streptomyces sp.YN86 
(KJ721165.1) paulomycin biosynthesis clusters. On the 
other hand, Plm19 show similarity to GCN5-related 
N-acetyltransferase bthur0008_41520 (ZP_04104064.1). 
However, Plm19 has no orthologues annotated in pau-
lomycin biosynthesis clusters in S. paulus (KJ721164.1) 
and Streptomyces sp.YN86 (KJ721165.1) [33], but the cor-
responding gene is present in both sequences between 
pau21 and pau22 in S. paulus NRRL8115 and pauY21 
and pauY22 in Streptomyces sp.YN86.
Fig. 4 Characterization of genes encoding glycosyltransferases. 
UPLC chromatograms, monitored at 244 nm, of S. albus J1074 mutant 
strains altered in paulomycins biosynthesis by inactivation of glyco-
syltransferase coding genes plm12 (SAM5324) and plm23 (SAM5335). 
All extracts were generated by culturing mutant strains in R5A liquid 
medium during 96 h. Labeled peaks correspond to paulomycin A (1), 
paulomycin B (2), paulomenol A (4), paulomenol B (5), 6-hydroxyl-
paulinone (6), (2E)-17-(4′-aminophenyl)-3,11,15-trihydroxy-10,12,14-
trimethyl-17-oxo-heptadeca-4,6,8-trienoic acid (7), 2-aminobenzoic 
acid (anthranilic acid) (8), compound not characterized (9*), 
N-acetyl-orto-aminobenzoic acid (10), deoxydehydrochorismic acid 
(11)
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Inactivation of plm3 led to SAM5315 mutant strain that 
produced (Fig. 6) compound 10 and novel compound 12 
with UPLC retention time of 4.2 min, which shows a pau-
lomycin absorption spectrum with maxima at 238, 275 
and 318 nm, and a mass of m/z 703 [M + H]+. Charac-
terization of compound 12 by NMR (Additional file  3: 
Figures S30–S37, Table S5) identified it as paulomycin F 
(Fig.  5), a paulomycin E derivative previously described 
[22] that contain a reduced keto group at paulomycose 
moiety. Paulomycin F (12) is a paulomycin intermedi-
ate since it was converted into paulomycin A and B by 
feeding it to S. albus SAM3335 mutant strain (data not 
shown). In addition, SAM5315 also accumulated, in 
higher amounts than the wild type strain, a compound 
with UPLC retention time of 2.2 min previously observed 
in S. albus J1074 [14] that corresponds to antimycins bio-
synthetic intermediate antimycic acid (13) (Fig. 6).
SAM5331 mutant strain, generated by deleting plm19, 
was also unable to produce paulomycins (Fig.  6) and 
instead produced N-acetyl-orto-benzoic acid (10) and 
2-aminobenzoic acid (8) (Fig.  5). In addition, SAM5334 
mutant strain, generated by deleting plm22, was unable 
to produce paulomycins (Fig. 6) but it produced instead 
low amounts of 2-aminobenzoic acid (8) and three novel 
compounds, 14, 15 and 16 with UPLC retention times 
of 3.9, 4.7 and 5.0  min, paulomycin absorption spec-
trum with maxima at 234, 275 and 323 nm, and masses 
of m/z 659, 731 and 745 [M +  H]+, respectively. These 
masses are in concordance with paulomycin E, B and A 
derivatives 13-O-deacetyl-paulomycin E (14), 13-O-dea-
cetyl-paulomycin B (15) and 13-O-deacetyl-paulomycin 
A (16) (Fig.  5). Co-culture of SAM5335 and SAM5334 
showed the conversion of 13-O-deacetyl-paulomycin E 
(14), 13-O-deacetyl-paulomycin B (15) and 13-O-dea-
cetyl-paulomycin A (16) into paulomycin A (1) and B (2) 
(Additional file 2: Figure S7), result that implies there are 
two alternative pathways for paulomycin A and B biosyn-
thesis starting from 13-O-deacetyl-paulomycin E (14) 
(Figs.  7 and 8). As in the case of 6-hydroxyl-paulinone 
(6) described above, 13-O-deacetyl-paulomycin E (14), 
13-O-deacetyl-paulomycin B (15) and 13-O-deacetyl-
paulomycin A (16) suffered, during their purification 
Fig. 5 Proposed origin of compounds accumulated by S. albus J1074 mutant strains altered in paulomycins biosynthesis. Paulomycin biosynthesis 
orthologues from S. paulus NRRL8115 [33] are depicted in parenthesis. Compounds are pointed by dotted arrows starting from the compound they 
might derive. ADIC, 2-amino-2-deoxyisochorismate; DHHA, 2,3-dihydro-3-hydroxyanthranilate; PABA, p-aminobenzoic acid; PKS, polyketide synthase
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and analysis, an acyl migration of the paulic acid moi-
ety. Thus, characterization of these compounds by NMR 
(Additional file 3: Figures S38–S61, Tables S1–S8) iden-
tified them as 13-O-deacetyl-13-O-paulyl-paulomycin 
E (14′), 13-O-deacetyl-13-O-paulyl-paulomycin B (15′) 
and 13-O-deacetyl-13-O-paulyl-paulomycin A (16′) 
(Scheme  2). Compounds 14′, 15′ and 16′ are not real 
paulomycin biosynthetic intermediates since no conver-
sion to paulomycin A and B was observed by feeding to 
S. albus SAM5335 mutant strain. Complementation of 
SAM5315, SAM5331 and SAM5334 using pEM4HT5315, 
pEM4HT5331 and pEM4HT5334, respectively, partially 
restored (70, 50 and 50 %, respectively) paulomycins and 
paulomenols biosynthesis (Additional file 1: Figure S5).
Enzymes involved in paulic acid biosynthesis
Several activities might be involved in the biosynthesis 
of the paulic acid moiety. Paulic acid contains an iso-
thiocyanate residue (−N =  C =  S) that determines the 
paulomycin characteristic absorbance peak at 275  nm 
and confers antibiotic activity to paulomycins [23]. Since 
the isothiocyanate moiety presents nitrogen and sulfur 
atoms there must be in the cluster, genes encoding an 
aminotransferase and a sulfotransferase involved in the 
introduction of these components. In the biosynthesis 
cluster, plm28 encodes a protein containing an UBA/
THIF-type NAD/FAD binding fold (IPR000594) that 
might act as a sulfotransferase based on the similarity to 
MoeZ-like enzymes, which transfer sulfur during molyb-
dopterin biosynthesis [35]. On the other hand, plm29 
encodes a putative aminotransferase. For both enzymes, 
Plm28 and Plm29, there are orthologues (Pau30/PauY30 
and Pau31/PauY31) annotated in paulomycin biosynthe-
sis clusters of S. paulus (KJ721164.1) and Streptomyces 
sp.YN86 (KJ721165.1), respectively.
Inactivation of plm28 led to SAM5340 mutant strain, 
unable to produce paulomycins or any other related 
compound (Fig.  9). Similarly, deletion of plm29 led 
to SAM5341 mutant, unable to produce paulomycins 
but that accumulated compounds 8, 10 and antimy-
cic acid (13) (Fig.  9). Complementation of SAM5340 
and SAM5341 using pEM4HT5340 and pEM4HT5341, 
respectively, restored paulomycins and paulomenols pro-
duction at different levels: to wild type yield in the case of 
mutant SAM5340 and to 40 % of wild type levels in the 
case of mutant SAM5341 (Additional file 1: Figure S5).
Biosynthesis of L‑paulomycose and generation of novel 
paulomycin derivatives
The paulomycin biosynthesis gene cluster contains all 
genes necessary for the biosynthesis of L-paulomycose. 
An intermediate in the biosynthesis of L-olivose, NDP-4-
keto-L-olivose [36], might be generated by the activity of 
d-glucose-1-phosphate synthase Plm21, dTDP-glucose 
4,6-dehydratase Plm20, NDP-hexose 2,3-dehydratase 
Plm13, dTDP-4-keto-6-deoxy-L-hexose 2,3-reductase 
Plm40 and dTDP-4-keto-6-deoxyhexose 3,5-epimerase 
Plm42. The intermediate NDP-4-keto-L-olivose might 
then suffer an O-methylation, most probably by dTDP-
6-deoxy-L-hexose 3-O-methyltransferase Plm41, and 
the incorporation of a two-carbon side chain at C4 to 
generate L-paulomycose (Fig. 7). Two enzymes from the 
pathway with high similarity to pyruvate dehydrogenase 
E1 α and β subunits, Plm8 and Plm9, might participate 
in the incorporation of such side chain. A similar mecha-
nism has been shown to participate in the biosynthesis 
of kosinostatin [37], it has been biochemically charac-
terized in yersinose A biosynthesis [38], and it has been 
genetically elucidated in avilamycin A pathway [39]. In all 
those cases the mechanism involves the transfer of a two-
carbon side chain into the deoxysugar from pyruvate. All 
enzymes involved in L-paulomycose biosynthesis men-
tioned in this section present orthologues into paulomy-
cin biosynthesis clusters in S. paulus and Streptomyces 
sp.YN86 (Table 1).
An S. albus J1074 mutant strain (∆SUG) was gener-
ated by simultaneous deletion of three genes that might 
Fig. 6 Characterization of genes encoding acyltransferases. UPLC 
chromatograms, monitored at 244 nm, of S. albus J1074 mutant 
strains altered in paulomycins biosynthesis by inactivation of 
acyltransferase coding genes plm3 (SAM5315), plm19 (SAM5331) 
and plm22 (SAM5334). Extracts were generated by culturing mutant 
strains in R5A liquid medium during 96 h. Labeled peaks correspond 
to paulomycin A (1), paulomycin B (2), paulomenol A (4), paulome-
nol B (5), 2-aminobenzoic acid (anthranilic acid) (8), compound not 
characterized (9*), N-acetyl-orto-aminobenzoic acid (10), deoxyde-
hydrochorismic acid (11), paulomycin F (12), antimycic acid (13), 
13-O-deacetyl-paulomycin E (14), 13-O-deacetyl-paulomycin B (15) 
and 13-O-deacetyl-paulomycin A (16)
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Fig. 7 Proposed paulomycin A and B biosynthesis pathway (Route A). Orthologues from S. paulus NRRL8115 [33] are depicted in parenthesis. Last 
step in paulomycose by incorporation of a pyruvate unit has been previously characterized biochemically in C4-branched 3,6-dideoxyhexose 
yersiniose A biosynthesis [38]. ADIC, 2-amino-2-deoxyisochorismate; DAHP, 3-deoxy-D-arabinose-heptulosonic 7-phosphate; DHHA, 2,3-dihydro-
3-hydroxyanthranilate; E4P, erythrose-4-phosphate; 3-HAA, 3-hydroxyanthranilic acid; PEP, phosphoenolpyruvate
Fig. 8 Proposed paulomycin A and B biosynthesis pathway from 13-O-deacetyl-paulomycin E (Route B)
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be involved in L-paulomycose biosynthesis: plm40, plm41 
and plm42, encoding a dTDP-4-keto-6-deoxy-L-hexose 
2,3-reductase, a dTDP-6-deoxy-L-hexose 3-O-methyl-
transferase and a dTDP-4-keto-6-deoxyhexose 3,5-epime-
rase, respectively. As expected, UPLC analysis of the 
products accumulated by ∆SUG (Fig. 10a) showed it was 
unable to produce paulomycins A or B but that produced 
instead 6-hydroxyl-paulinone (6) (Fig. 5). This compound 
has been previously observed in SAM5324 mutant strain 
(Fig. 4) that lacks L-paulomycose glycosyltansferase Plm12.
∆SUG mutant strain was used as recipient to host plas-
mid pFL844T [40] that contains all genes required for 
the biosynthesis of L-amicetose and L-olivose. Plasmid 
pFL844T contains, in addition, a 3-O-methyltransferase 
coding gene (oleY). OleY is able to introduce an O-methyl 
group into L-olivose and other deoxysugar moieties [41]. 
The resultant strain ∆SUG/844 showed the appearance 
of five new UPLC peaks (Fig. 10a), with retention times 
of 4.0 min (17), 4.7 min (18), 4.9 min (19), 5.3 min (20) 
and 5.7 min (21). These compounds showed the charac-
teristic paulomycin absorption spectrum with maxima 
at 236, 275 and 323  nm, and possessed masses of m/z, 
687 [M + H]+ (17), 759 [M + H]+ (18), 773 [M + H]+ 
(19), 757 [M + H]+ (20) and 743 [M + H]+ (21). NMR 
characterization of these paulomycin derivatives (Addi-
tional file  3: Figures S62–S95, Tables S9–S10) showed 
they correspond to: 3′-O-demethyl-paulomycin E (17), 
3′-O-demethyl-paulomycin B (18), 3′-O-demethyl-pau-
lomycin A (19), 3′-demethoxyl-paulomycin A (20) and 
3′-demethoxyl-paulomycin B (21) (Fig.  10b). All these 
compounds are novel derivatives of paulomycin A, B 
and E with modifications at the C3′ position of the deox-
ysugar, lacking the methoxy group (compounds 20 and 
21) or the O-methyl group (compounds 17, 18 and 19). 
Curiously, no compounds that present a 3′-O-methyl-
ation, showing the effect of OleY, have been identified. 
O-methyltransferase OleY has been previously reported 
to methylate the C3′ hydroxyl group of different deox-
ysugars, including L-olivose, when attached to macrolide 
or anthracycline type compounds [41, 42].
Fig. 9 Characterization of genes involved in paulic acid biosynthesis. 
UPLC chromatograms, monitored at 244 nm, of S. albus J1074 mutant 
strains altered in paulomycins biosynthesis by inactivation of plm28 
(SAM5340) and plm29 (SAM5341) involve in paulic acid biosynthesis. 
Extracts were generated by culturing mutant strains in R5A liquid 
medium during 96 h. Labeled peaks correspond to paulomycin A (1), 
paulomycin B (2), paulomycin E (3), paulomenol A (4), paulomenol 
B (5), 2-aminobenzoic acid (anthranilic acid) (8), N-acetyl-orto-amin-
obenzoic acid (10), deoxydehydrochorismic acid (11)
Fig. 10 Generation of novel paulomycin derivatives. a UPLC chromatograms, monitored at 244 nm, of S. albus J1074 mutant strain ∆SUG, altered in 
L-paulomycose biosynthesis by deletion of plm40, plm41 and plm42, and ∆SUG strain carrying pFL844T (∆SUG/844). b Chemical structures of novel 
paulomycin derivatives
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Biological activity of novel paulomycins
The antibacterial activity of paulomycin A (1), paulomycin 
B (2), paulomycin E (3), paulomycin F (12), 13-O-deacetyl- 
13-O-paulyl-paulomycin E (14′), 13-O-deacetyl-13-O-
paulyl-paulomycin B (15′), 13-O-deacetyl-13-O-paulyl-
paulomycin A (16′), 3′-O-demethyl-paulomycin B (18), 
3′-O-demethyl-paulomycin A (19), 3′-demethoxyl-paulo-
mycin A (20) and 3′-demethoxyl-paulomycin B (21) was 
monitored against Gram-positives Micrococcus luteus, 
Staphylococcus aureus, S. epidermidis, and Streptococcus 
agalactiae, and Gram-negatives Escherichia coli, Pseu-
domonas aeruginosa, Serratia marcenscens and Klebsiella 
pneumonia.
Paulomycins A (1), B (2), E (3) and F (12) showed a 
good antibacterial activity against all Gram-positive 
bacteria tested, being more active against S. agalactiae 
with inhibition halos of 21, 21, 19 and 18  mm, respec-
tively (Additional file 4: Figure S96). Paulomycin deriva-
tives carrying modifications in the L-paulomicose moiety 
(compounds 18, 19, 20 and 21) retain antibacterial activ-
ity but were less active than paulomycins A and B. The 
best activity observed was also against S. agalactiae, 
being the most active 3′-O-demethyl-paulomycin A (19) 
with an inhibition halo of 20  mm. Paulomycin deriva-
tives carrying an acyl migration of paulic acid to the C13 
hydroxyl group (compounds 14′, 15′ and 16′) showed no 
antibacterial activity against the Gram-positive bacteria 
tested (Additional file  4: Figure S96). All paulomycins 
and their derivatives were found inactive against the all 
Gram-negative bacteria tested.
Discussion
Genome mining of S. albus J1074 chromosome sequence 
predicted the presence of 27 gene clusters putatively 
involved in secondary metabolites biosynthesis [14]. Five 
of these clusters were found to direct the biosynthesis of 
different metabolites: blue pigment indigoidine, polycy-
clic tetramate macrolactam 6-epi-alteramides, polyene 
candicidins, non-ribosomal peptide antimycins and gly-
cosylated antibiotic paulomycins [14]. Paulomycin bio-
synthesis gene cluster was initially reported to comprise a 
region of approximately 60 kb from sshg_05313 (plm1) to 
sshg_05354 (plm42) based on in silico analysis [14]. These 
limits have been confirmed in this work by analysis of 
gene expression and gene inactivation experiments. Pro-
duction of paulomycins by S. albus J1074 was previously 
reported to be very variable and a reproducible pattern 
for production of these compounds was not achieved 
using different batches of media or changing the culture 
conditions [14]. Furthermore, paulomenols, initially pro-
posed to be paulomycins intermediates [23], were found 
to be paulomycins degradation products [14]. More 
recently, additional biosynthesis gene clusters involved in 
paulomycins biosynthesis have been reported at S. pau-
lus NRRL8115 and Streptomyces sp. YN86, and a putative 
biosynthesis pathway has been proposed base on in silico 
analysis [33].
In addition to a clear instability of paulomycins, which 
turn into paulomenols by loss of the paulic acid moiety 
[14], paulomycins intermediates also showed structural 
instability since products expected to be accumulated 
by mutant strains generated in this work were mostly 
degraded or modified into shunt products. According 
to their respective accumulated products, these mutant 
strains can be divided in two groups: (i) one group includ-
ing mutant strains affected in steps occurring before pau-
lic acid incorporation (SAM5331, SAM5335, SAM5340 
and SAM5341) and (ii) a second group including mutant 
strains defective in enzymes acting in late steps once 
paulic acid has been incorporated into the correspond-
ing intermediate (SAM5315, SAM5324, SAM5334 and 
∆SUG). On the basis of all these mutants a pathway for 
paulomycins biosynthesis is proposed (Fig. 7).
The first set of mutant strains are affected in genes cod-
ing for: acyltransferase Plm19, which we propose to be 
involved in the incorporation of paulic acid while Li and 
coworkers [33] proposed to be performed by 3-oxoacyl-
ACP synthase III Pau29 (Plm27); C-glycosyltrasferase 
Plm23; sulfotransferase Plm28; and aminotransferase 
Plm29, the last two enzymes likely involved in paulic acid 
biosynthesis. These mutants accumulate shunt products 
that do not contain paulic acid: 2-aminobenzoic acid (8), 
N-acetyl-orto-aminobenzoic (10) and deoxydehydro-
chorismic acid (11). 2-aminobenzoic acid (anthranilic 
acid, 8), might derive from DHHA dehydration (Fig. 5). 
Anthranilic acid should also be the intermediate leading 
to N-acetyl-orto-aminobenzoic (10) by N-acetylation. 
Aminotransferase Plm29 might be involved in paulic acid 
biosynthesis and acyltransferase Plm19 should transfer 
the paulic acid moiety to an early paulomycin intermedi-
ate in form of C-glycosylated quinone (Fig. 7). This puta-
tive glycosylated intermediate has not been identified in 
the aminotransferase and acyltransferase mutants. Per-
haps it is unstable and therefore leads to the accumula-
tion of early precursors that are then transformed into 
anthranilic acid (8) and N-acetyl-orto-aminobenzoic 
(10). The fact that inactivation of plm23 led also to accu-
mulate N-acetyl-orto-aminobenzoic (10) points to Plm23 
C-glycosyltransferase acting at early stages of paulomycin 
biosynthesis on a quinone intermediate that has not been 
detected in SAM5322 mutant strain. Thus, this uniden-
tified quinone intermediate might, in addition, be unsta-
ble (Fig. 5). The same interpretation can be applied to the 
accumulation of deoxydehydrochorismic acid (11), prob-
ably generated by chorismate dehydration, by SAM5335 
mutant strain. Other compounds not characterized, such 
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as 9, produced by SAM5331, SAM5341 and SAM5335 
strains, shared similar absorption spectrum to 
N-acetyl-orto-aminobenzoic (10), 2-aminobenzoic acid 
(anthranilic acid) (8) and deoxydehydrochorismic acid 
(11) and possess masses lower than 150 Daltons pointing 
to possible modification of other paulomycin intermedi-
ates such as 2-amino-2-deoxyisochorismate (ADIC) or 
3-hydroxyanthranilic acid (3-HAA) (Figs. 5, 7).
The second set of mutant strains mentioned above are 
defective at: acyltransferase Plm3, responsible for con-
version of paulomycin F (12) into paulomycin A (1) and 
B (2) by incorporation of 2-methylbutyrate and isobu-
tyrate, respectively; glycosyltransferase Plm12, involved 
in incorporation of paulomycose; acyltransferase Plm22 
(Pau24), which incorporates acetate into 13-O-deacetyl-
paulomycin E (14) to generate paulomycin E (3) in a 
different way as it was proposed previously [33] involv-
ing the incorporation of an acetyl group into TDP-D-
allose prior to its attachment to the quinone moiety; 
and enzymes involved in L-paulomycose biosynthesis: 
dTDP-4-keto-6-deoxy-L-hexose 2,3-reductase Plm40, 
dTDP-6-deoxy-L-hexose 3-O-methyltransferase Plm41, 
and dTDP-4-keto-6-deoxyhexose 3,5-epimerase Plm42 
(Fig. 7). These mutants accumulated compounds contain-
ing paulic acid. SAM5324 and ∆SUG mutant strains pro-
duce 6-hydroxyl-paulinone (6). SAM5315 mutant strain 
produces intermediate paulomycin F that might derive of 
paulomycin E by reduction of paulomycose keto group 
leading to a hydroxyl group (Fig. 5). On the other hand, 
SAM5334 produces 13-O-deacetyl-paulomycin A (16) 
and 13-O-deacetyl-paulomycin B (15) that might origi-
nate from 13-O-deacetyl-paulomycin E (14) (paulomycin 
intermediate also identified at SAM5334) by incorpora-
tion of 2-methylbutyrate and isobutyrate, respectively 
(Fig. 5). These results point acyltranferase Plm3 is a flex-
ible enzyme, capable of introducing 2-methylbutyrate 
and isobutyrate either on paulomycin F (12) (Fig.  7) or 
on13-O-deacetyl-paulomycin F (Fig.  8). Furthermore, 
since 13-O-deacetyl-paulomycin E (14), 13-O-deacetyl-
paulomycin A (16) and 13-O-deacetyl-paulomycin B (15) 
can be converted into paulomycin E, A and B, respec-
tively, acyltransferase Plm22 must also be flexible enough 
to introduce acetate into those compounds (14, 15 and 
16), acting in an alternative pathway (Route B) for the 
transformation of 13-O-deacetyl-paulomycin E (14) into 
paulomycin A (1) and B (2) (Fig.  8). Compounds 6, 14, 
15 and 16, lacking the acetate moiety at C13 hydroxyl 
group, suffer a paulic acid migration to that position, 
thus becoming shunt products: 6-hydroxyl-13-O-paulyl-
paulinone (6′), 13-O-deacetyl-13-O-paulyl-paulomycin 
E (14′), 13-O-deacetyl-13-O-paulyl-paulomycin B (15′) 
and 13-O-deacetyl-13-O-paulyl-paulomycin A (16′). 
Migration of acyl groups in aqueous solutions has been 
demonstrated to occur in other compounds such as beta-
cyanins where glucose 6′-O-position is always favored 
[43], thuggacins that suffer acyl migrations of their lac-
tone group [44], and chloramphenicol that undergoes an 
intra molecular rearrangement of an acetyl group from 
3-hydroxyl to 1-hydroxyl group [45]. It has been demon-
strated that acyl migration occurs to primary hydroxyl 
groups, which is the most stable position for acyl moie-
ties [46, 47]. Stabilization of paulic acid to its natural 
position at C11 might be determined by transferring ace-
tate at C13 hydroxyl group by acyltransferase Plm22.
Regarding paulic acid biosynthesis, in addition to sul-
fotransferase Plm28 and aminotransferase Plm29, some 
other activities are necessary for its biosynthesis, (Fig. 7). 
However, the lack of compounds containing incomplete 
versions of paulic acid being produced by SAM5340 
or SAM5341 mutants suggest a high specificity of acyl-
transferase Plm19 for paulic acid and makes characteri-
zation of this subpathway a complex issue that might be 
addressed in a different work. A related issue is paulic 
acid biosynthetic origin. Based on structural similari-
ties, paulic acid might derive from butyrate or crotonate 
(Fig. 7). If butyrate corresponds to the real precursor then 
feeding experiments using valine or isoburyrate should 
increase the production of all paulomycins (A, B, C and 
E), but only enhanced production of paulomycin B has 
been reported [30].
The expression of pFL844T, containing a set of deox-
ysugar biosynthesis genes for the biosynthesis of L-ami-
cetose and L-olivose, into ∆SUG mutant strain, affected 
in the biosynthesis of L-paulomycose, led to the genera-
tion of new glycosylated forms of paulomycins. The pro-
duction of such derivatives shows that L-paulomycosyl 
glycosyltransferase Plm12 possesses a certain degree 
of flexibility for the transfer of different deoxysugars. In 
addition, the pyruvate dehydrogenase system form by 
Plm8 and Plm9 is also flexible to catalyze the attachment 
of a two-carbon side chain, derived from pyruvate, into 
both 2,6-dideoxyhexoses and 2,3,6-trideoxyhexoses. On 
the other hand, O-methyltransferase OleY, which has 
been previously shown to be flexible for modification of 
deoxysugar moieties attached into macrolide or anthra-
cycline type aglyca [41, 42], is not apparently able to 
methylate 3′-O-demethyl-paulomycin E (17), 3′-O-deme-
thyl-paulomycin B (18) or 3′-O-demethyl-paulomycin A 
(19), which will lead to recover the production of pau-
lomycin A, B and E. Bioactivity testing of this paulo-
mycin derivaties showed that the removal of either the 
L-paulomycose moiety C3′ methoxy group (compounds 
20 and 21) or the O-methyl group (compounds 18 and 
19) clearly decreases the antibacterial activity of the com-
pounds with respect to paulomycin A and B. In contrast, 
the acyl migration of paulic acid to the C13 hydroxyl 
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group due to the absence of the characteristic acetate 
moiety (compounds 14′, 15′ and 16′) render these paulo-
mycin derivatives inactive.
Paulomycin biosynthesis has been shown to be 
repressed by afsA-y, γ-butyrolactone synthase gene in 
Streptomyces sp. YN8 [48]. However, there is not an afsA 
homologue present in S. albus J1074 or S. paulus NRRL 
8115 [48], indicating that the upper (pleiotropic) level of 
paulomycin regulation is strain-specific. Regulation of 
paulomycins biosynthesis is controlled in S. albus J1074 
by at least three pathway-specific regulatory systems: 
LuxR-family Plm2, SARP-family Plm10 and LuxR-family 
Plm30. Inactivation of genes encoding the last two tran-
scriptional regulators abrogates paulomycin production, 
while inactivation of plm2 led to a considerable reduction 
of paulomycins yields (20  %). On the other hand, plm1 
encoding a TetR-family transcriptional regulator acts as 
a repressor of the pathway since its inactivation lead to 
an increased production of paulomycin B and paulome-
nol B.
Conclusions
We have unraveled paulomycins biosynthesis pathway by 
inactivation of genes encoding glycosyltransferases, acyl-
transferases and enzymes involved in paulic acid biosyn-
thesis. These experiments have allowed the assignment of 
each of these genes to specific paulomycin biosynthesis 
steps based on characterization of products accumulated 
by the corresponding mutant strains. In addition, novel 
derivatives of paulomycin A, B and E containing L-pau-
lomycose modified moieties were generated by combi-
natorial biosynthesis. The production of such derivatives 
shows that L-paulomycosyl glycosyltransferase Plm12 
possesses a certain degree of flexibility for the transfer of 
different deoxysugars. Furthermore, the pyruvate dehy-
drogenase system formed by Plm8 and Plm9 is also flexi-
ble to catalyze the attachment of a two-carbon side chain, 
derived from pyruvate, into both 2,6-dideoxyhexoses and 
2,3,6-trideoxyhexoses. Bioactivity testing of paulomy-
cin derivatives showed that the L-paulomycose moiety 
C3′ methoxy group is important for the bacterial activity 
since those compounds lacking this group are less active 
than their corresponding counterparts. In addition, the 
paulic acid moiety is not only essential for paulomycins 
antibacterial activity but also its location is important. 
The lack of the D-allose acetate moiety and its substitu-
tion by a paulic acid moiety renders the corresponding 
paulomycin derivatives inactive as antibacterial agents.
Methods
Strains and culture conditions
Bacterial strains used in this work were S. albus J1074 
[15] and S. albus B29 [14]. Escherichia coli DH10B 
(Invitrogen) and ET12567 (pUB307) [49] were used for 
subcloning and intergeneric conjugation, respectively. 
Growth medium for S. albus was tryptone soya broth 
(TSB), MA medium was used for sporulation and R5A 
as regular production medium [50]. MFE medium (Glu-
cose (10  g/L), Soy bean flour (5  g/L), MOPS (21  g/L), 
Yeast extract (0.2  g/L), MgSO4·7H2O (0.6  g/L), K2HPO4 
(1.75  g/L), CaCl2 (5  mg/L), MnCl2 (1  mg/L), ZnSO4 
(1 mg/L), FeSO4 (5 mg/L), pH 6.8) was used for produc-
tion and purification of compounds 6, 12, 14, 15, 16, 17, 
18, 19, 20 and 21. E. coli media were those described in 
the literature (LB and TB) [51]. When plasmid-contain-
ing clones were grown, media were supplemented with 
appropriate antibiotics: ampicillin (100 µg/mL), tobramy-
cin (20  µg/mL), apramycin (25  µg/mL), thiostrepton 
(50  µg/mL), tetracycline (10  µg/mL), chloramphenicol 
(25 µg/mL) and nalidixic acid (50 µg/mL).
DNA manipulation and plasmids
DNA manipulations were performed according to stand-
ard procedures for E. coli [51] and Streptomyces [49]. PCR 
conditions used for all amplifications were 99.9  °C for 
4 min; 20 cycles of 99.9 °C for 20 s, 65–45 °C touchdown 
for 20 s and 72 °C for 45 s followed by 10 cycles of 99.9 °C 
for 20 s, 60 °C for 20 s and 72 °C for 45 s. Final extension 
was performed at 68 °C for 10 min. Pfx DNA polymerase 
(Invitrogen) and 2.5 % dimethylsulphoxide (DMSO) were 
used for all amplifications. PCR products of the expected 
sizes were initially cloned into pCR-BLUNT for sequenc-
ing verification. All oligoprimers used for PCR amplifica-
tions are shown in Additional file  1: Table S1. Plasmids 
used in this work were: pOJ260 [52] for gene disruption; 
pEFBAoriT [53] and pHZ1358 [54] for gene replacement; 
pEM4T [55] was used for gene expression; pLHyg [56] 
was the source of the hygromycin resistance gene hyg; 
and pCR-BLUNT (Invitrogen) was used for cloning PCR 
products. Plasmid pFL844T [40] was used for the gen-
eration of novel paulomycin derivatives by combinatorial 
biosynthesis.
Methods regarding the construction of plasmids for 
gene inactivation and ectopic expression and the gen-
eration of S. albus J1074 mutant strains are provided in 
Additional file 1. Methods for co-culture experiment are 
provided in Additional file 2.
Isolation of total RNA and gene expression analysis
Mycelium from R5A liquid cultures of S. albus J1074 
was obtained at 48  h following a previously described 
procedure [57]. Transcript detection analysis was car-
ried out by using the SuperScript one-step RT-PCR 
with Platinum® Taq DNA polymerase (Invitrogen) with 
100  ng of total RNA as a template. Dimethyl sulphox-
ide (5 % v/v, final) was added to all reactions along with 
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RNAguard RNase inhibitor (32.2 U per reaction) (Amer-
sham Pharmacia Biotech, Europe GmbH, Barcelona, 
Spain). Conditions were those described before [57] but 
using specific amplification temperatures depending of 
each set of primers. Primers listed in Additional file  1: 
Table S1 were used to generate PCR products of differ-
ent lengths around 500  bp. Negative controls for each 
pair of primers were carried out with Platinum® Taq 
DNA polymerase (Invitrogen) in the absence of reverse 
transcriptase to confirm that amplified products were not 
due to the presence of contaminating chromosomal DNA 
in RNA preparations. Oligonucleotides HRDB-GB1-F 
and HRDB-GB2-R for hrdB [57, 58], encoding a constitu-
tively expressed housekeeping sigma factor, were used as 
an internal control to normalize RNA samples. RT-PCR 
analysis were carried out at least three times for each pair 
of primers and the RT-PCR products were separated in 
agarose gels and visualized by ethidium bromide staining. 
Identity of PCR products was verified by direct sequenc-
ing with one of the amplification primers.
Analysis of metabolites by UPLC and HPLC–MS 
and isolation of compounds
Whole cultures of S. albus J1074 and mutants gener-
ated in this work were extracted with ethyl acetate con-
taining formic acid (1  %), to enhance the extraction of 
compounds containing ionizing groups, and analyzed 
by UPLC and LC–MS for the production of paulomy-
cins, following previously described methods [14, 59]. 
Reversed phase chromatography was performed in an 
Acquity UPLC instrument fitted with a BEH C18 col-
umn (1.7  µm, 2.1  ×  100  mm, Waters). Samples were 
eluted with 10  % acetonitrile for 1  min, followed by a 
linear gradient from 10 to 100 % acetonitrile over 7 min, 
at a flow rate of 0.5 mL/min and a column temperature 
of 35  °C. For HPLC–MS analysis, an Alliance chroma-
tographic system coupled to a ZQ4000 mass spectrom-
eter and a SunFire C18 column (3.5 µm, 2.1 × 150 mm, 
Waters) was used. Solvents were the same as above and 
elution was performed with an initial isocratic hold with 
10 % acetonitrile during 4 min followed by a linear gradi-
ent from 10 to 88 % acetonitrile over 26 min, at 0.25 mL/
min. MS analysis were done by electrospray ionization in 
the positive mode, with a capillary voltage of 3 kV and a 
cone voltage of 20 V. Detection and spectral characteriza-
tion of peaks was performed in both cases by photodiode 
array detection in the range from 200 to 500  nm, using 
Empower software (Waters) to extract bidimensional 
chromatograms at different wavelengths, depending on 
the spectral characteristics of the desired compound.
Isolation of compounds accumulated by S. albus J1074 
mutants SAM5315, SAM5324, SAM5331, SAM5334, 
SAM5335 and ∆SUG, affected in the production of 
paulomycins was performed following the procedure 
previously described for isolation of paulomycins [59].
Structural characterization of compounds
Compounds 6′, 7, 8, 10, 11, 12, 14′, 15′, 
16′, 17, 18, 19, 20 and 21 corresponding to 
6-hydroxyl-13-O-paulyl-paulinone (6′), (2E)-17-
(4 ′-aminophenyl)-3 ,11,15- tr ihydroxy-10,12,14-
trimethyl-17-oxo-heptadeca-4,6,8-trienoic acid (7), 
2-aminobenzoic acid (anthranilic acid) (8), N-acetyl-orto-
aminobenzoic acid (10), deoxydehydrochorismic acid 
(11), paulomycin F (12), 13-O-deacetyl-13-O-paulyl-
paulomycin E (14′), 13-O-deacetyl-13-O-paulyl-paulo-
mycin B (15′), 13-O-deacetyl-13-O-paulyl-paulomycin A 
(16′), 3′-O-demethyl-paulomycin E (17), 3′-O-demethyl-
paulomycin B (18), 3′-O-demethyl-paulomycin A (19), 
3′-demethoxyl-paulomycin A (20) and 3′-demethoxyl-
paulomycin B (21) were subjected to LC/ESI-TOF anal-
ysis in order to determine their molecular formula. The 
structural elucidation of compounds 6′, 7, 8, 10, 11, 12, 
14′, 15′, 16′, 17, 18, 19, 20 and 21 was carried out by 
analysis of a combination of 1D (1H and 13C), and 2D (1H-
1H COSY, TOCSY, 1H-13C heteronuclear single-quantum 
correlation (HSQC)-edited and 1H-13C heteronuclear 
multiple-bond correlation (HMBC) NMR experiments 
and comparison of the spectra obtained with those 
described in the literature (supporting information). Sol-
vents used in the NMR analyses were deuterated metha-
nol (CD3OD) for compounds 8, 10 and 11, or deuterated 
DMSO (DMSO-d6) for compounds 6′, 7, 12, 14′, 15′,16′, 
17, 18, 19, 20 and 21 (Additional file 3).
Methods regarding analysis of the antibacterial activity 
of paulomycins are provided in Additional file 4.
Additional files
Additional file 1. Methods. Construction of plasmids for gene inactiva-
tion and ectopic expression. Methods. Generation of S. albus J1074 
mutant strains. Table S1. Primers used in this work. Figure S1. PCR 
analysis of SAM5355, SAM5312 and SAM5313 mutant strains. Figure S2. 
PCR analysis of SAM5314, SAM5315 and SAM5322 mutant strains. Figure 
S3. PCR analysis of SAM5324, SAM5331, SAM5334 and SAM5335 mutant 
strains. Figure S4. PCR analysis of SAM5340, SAM5341, SAM5342 and 
DSUG mutant strains. Figure S5. Genetic complementation of S. albus 
J1074 mutant strains. Format: PDF.
Additional file 2. Methods. Co-culture experiments. Figure S6. Co-
culture of SAM5335 and SAM5324 mutant strains. Figure S7. Co-culture 
of SAM5335 and SAM5334 mutant strains. Format: PDF.
Additional file 3. Methods. LC/ ESI-TOF and NMR analyses and structural 
characterization of: 6-hydroxyl-13-O-paulyl-paulinone (6’) [Figures S8-
S14, and Table S2]; (2E)-17-(4’-aminophenyl)-3,11,15-trihydroxy-10,12,14-
trimethyl-17-oxo-heptadeca-4,6,8-trienoic acid (7) [Figures S15-S19, and 
Table S3]; 2-aminobenzoic acid (anthranilic acid) (8) [Figures S20-S23, 
and Table S4]; N-acetyl-orto-aminobenzoic acid (10) [Figures S24-S26]; 
deoxydehydrochorismic acid (11) [Figures S27-S29]; paulomycin F (12) 
[Figures S30-S37, and Table S5]; 13-O-deacetyl-13-O-paulyl-paulomycin 
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